Teva Refinanced Its Debt. The Stock Still Hasn't Earned Its Price.

Teva Pharmaceutical priced $4.9 billion in new senior notes on September 10, just six days after S&P Global upgraded the company to investment grade, completing a trio of upgrades from all three major rating agencies. The transaction replaces higher-coupon debt maturing between 2028 and 2031 with lower-cost obligations stretching to 2037. It is the kind of refinancing that, for most companies, passes without notice. For Teva, it marks the end of a long credit rebuild — and it raises a question about the stock that the bond market move does not answer: with the debt story now working in Teva's favor, does the equity price still offer a margin of safety?

The mechanics of the swap

Teva issued five tranches of new debt: $1.2 billion at 5.25% due 2032, $1.0 billion at 5.50% due 2034, $1.0 billion at 5.75% due 2037, plus euro-denominated notes at 4.25% (2033) and 4.625% (2036). These replace notes carrying coupons between 6.75% and 8.125% that would have come due between 2028 and 2031.

The coupon spread ranges from about 1.5 percentage points on the cheapest tranche to over 2.4 points on the most expensive. Across the full $4.9 billion, the annual interest savings land somewhere near $100 million. That is not a transformational number against $32 billion in total debt and roughly $915 million in annual net interest expense. But it is real cash flow that flows to equity holders, and it pushes Teva's nearest large maturities further away from the refinancing cliff that plagued the company a few years ago.

This is a refinancing, not a payoff. Total debt does not come down by $4.9 billion — it stays roughly level, just at cheaper rates and longer dates. The investor test here is whether the savings, combined with growing free cash flow, eventually bring leverage down enough to matter for the stock. Teva's own target is to reduce net leverage to 2x. Getting there requires more than coupon savings; it requires the cash flow engine to actually grow.

The credit upgrade sequence

The refinancing is the final act in a sequence that began more than a year ago. Fitch first upgraded Teva from junk to BBB- in May 2026. Moody's followed. S&P completed the move to investment grade on September 4, the same week Teva announced the new bond offering. All three agencies now rate the company at BBB- with a stable outlook.

The upgrades are not a gift. Fitch noted that Teva repaid more than $1.5 billion of debt each year from 2023 through 2025 and expects that pace to continue. S&P cited sustained growth in branded products, stabilization in generics, and a pipeline of late-stage assets. The credit agencies are telling the same story Teva's management has been repeating: the pivot from a generic-focused drugmaker, burdened by patent cliffs and high debt, to a balanced biopharma company is working. The evidence they point to is real. Revenue grew to $17.3 billion in 2025, a third consecutive year of growth. The three core innovative brands — Austedo, Ajovy, and Uzedy — generated $1 billion in combined quarterly sales during the fourth quarter.

What investment-grade status unlocks is borrowing capacity at substantially lower rates. Teva spent years financing at junk-bond spreads. That borrowing cost is embedded in every dollar of interest expense and weighed on every earnings report. Crossing the investment-grade threshold changes the cost of capital permanently, not just for this one deal but for every future issuance. That matters for a company that still carries $32 billion in debt and needs to roll maturities regularly.

Where the stock price disconnects

Here is where the bond story and the stock story diverge. The debt refinancing is sensible housekeeping at better rates. But the equity has already moved as if Teva has solved its long-term growth equation.

Shares at $37 represent a 89% return over the past year, from a 52-week low of $18.21. The market cap sits at $43 billion, with an enterprise value of $56 billion. The forward price-to-earnings multiple is 43.5x. EV/EBITDA is 21.7x. Compare that to Bristol-Myers Squibb, a larger pharma peer: BMY trades at 14x forward earnings and 8.3x EV/EBITDA. Teva is not just priced above its peer; it is priced as if it will sustainably deliver growth returns that do not yet exist in its financial statements.

The numbers on the other side of those multiples are modest. Free cash flow over the trailing twelve months is $1.35 billion — up 51% year over year, which is impressive, but a small base. That $1.35 billion against a $43 billion market cap implies a free cash flow yield of roughly 3%. The dividend yield is less than 1%. Return on invested capital is 6.6%. Return on equity is negative at -7.7%, reflecting the balance sheet weight.

None of those numbers is bad. They are not even unprofitable. They are simply not the return profile of a company that deserves to trade at 21.7x EV/EBITDA. That multiple belongs to businesses compounding cash flow at rates that justify it. Teva's adjusted EBITDA margin of roughly 19% is solid, but ROIC of 6.6% does not clear a reasonable cost of capital for a company that still carries meaningful leverage.

What the investor actually needs to believe

The bull case for Teva at this price does not rest on the refinancing. The refinancing is a hygiene factor — something that should happen, and did happen, at good terms. The stock's current valuation rests on the pipeline and the branded growth trajectory that management calls the "acceleration phase".

Teva projects Austedo alone will exceed $2.5 billion in sales by 2027 and $3 billion by 2030. The innovative franchise as a whole is targeted above $5 billion by 2030. Free cash flow is projected to reach $2.7 billion by 2027 and $3.5 billion by 2030. The pipeline includes duvakitug for inflammatory bowel disease (potential $2-5 billion peak), an olanzapine long-acting injectable (projected $1.5-2 billion franchise), and several other assets. Management's operating margin target is 30% by 2027.

These are not unreasonable projections. Austedo is already a $2.26 billion drug, ahead of its original growth plan. Uzedy holds over 60% market share in its segment. The biosimilar pipeline of 13 products could double biosimilar revenue by 2028. The problem is not that the projections are fabricated. The problem is that the stock price has already worked most of them in.

At 43x forward earnings, the market is pricing in nearly all of that growth and assuming it happens without major disruption. A missed regulatory deadline, competitive pressure on Austedo, or a slower-than-expected biosimilar rollout would mean the multiple compresses on weaker earnings growth — the worst outcome for a stock trading at a premium. That is the structural risk of buying a turnaround story after the stock has already nearly doubled.

The gap between price and provable value

The refinancing confirms that Teva's credit profile has repaired itself. The company can borrow at investment-grade rates, extend its maturity ladder, and save roughly $100 million a year in interest. That is a positive that flows to equity holders.

But it does not change the arithmetic of the stock. The provable cash flow today — $1.35 billion in free cash flow against a $43 billion market cap — yields roughly 3%. The enterprise value multiple of 21.7x EV/EBITDA is nearly three times what a comparable pharma peer commands. The company carries $32 billion in debt, a net debt figure of nearly $13 billion, and ROIC that does not yet clear its cost of capital. The gap between price and provable value is wide, and it runs in the direction of the stock being expensive, not cheap.

For an investor who already holds Teva and believes in the pipeline, the refinancing removes a risk. Maturity pressure is eased, borrowing costs come down, and the balance sheet becomes more manageable. For an investor considering a new position, the refinancing is not the reason to buy. The reason would have to be a conviction that the branded growth and pipeline will exceed the aggressive targets management has already set — because the current stock price already assumes they will.

The bond market gave Teva the grade it earned. The stock market has given it a price that requires the company to do even better.